Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.69 |
| ▸ | BRAF | P15056 | 6/20 | 0.60 |
| ▸ | RAF1 | P04049 | 5/20 | 0.60 |
| ▸ | SMO | Q99835 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7838506 | 0.91 | MAPK14 (0.70) | MAPK14BRAFRAF1 | |
| SCHEMBL5897136 | 0.88 | MAPK14 (0.75) | MAPK14BRAFRAF1 | |
| SCHEMBL6978618 | 0.88 | MAPK14 (0.65) | MAPK14BRAFRAF1 | |
| SCHEMBL5897801 | 0.87 | MAPK14 (0.79) | MAPK14BRAFRAF1 | |
| SCHEMBL7679107 | 0.86 | MAPK14 (0.72) | MAPK14BRAFRAF1SMO | |
| SCHEMBL6484389 | 0.85 | MAPK14 (0.70) | MAPK14BRAFRAF1SMO | |
| SCHEMBL6969309 | 0.85 | MAPK14 (0.62) | MAPK14BRAFRAF1 | |
| SCHEMBL6978621 | 0.85 | MAPK14 (0.66) | MAPK14BRAFRAF1 | |
| SCHEMBL16621429 | 0.84 | MAPK14 (0.66) | MAPK14BRAFRAF1 | |
| SCHEMBL12764085 | 0.84 | MAPK14 (0.69) | MAPK14BRAFRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737283-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-06-15 | — | — | US | disclosed |
| US-20090137021-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2009-05-28 | — | — | US | disclosed |
| US-20090105230-A1 | Anti-inflammatory medicaments | FLYNN DANIEL L | 2009-04-23 | — | — | US | disclosed |
| US-20090075986-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2009-03-19 | — | — | US | disclosed |
| US-20090069310-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2009-03-12 | — | — | US | disclosed |
| US-20080187978-A1 | Anti-inflammatory medicaments | FLYNN DANIEL L | 2008-08-07 | — | — | US | disclosed |
| US-20080132506-A1 | Anti-inflammatory medicaments | FLYNN DANIEL L | 2008-06-05 | — | — | US | disclosed |
| US-20080064688-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2008-03-13 | — | — | US | disclosed |
| US-20080045531-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2008-02-21 | — | — | US | disclosed |
| US-20070191336-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| US-7202257-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2007-04-10 | — | — | US | disclosed |
| US-6455520-B1 | TUMOR NECROSIS FACTOR AND INTERLEUKIN INHIBITORS; ANTIINFLAMMATORY AGENTS, ANTIALLERGENS; BONE DISORDERS | ASTRA ZENECA AB (SE) | 2002-09-24 | — | — | US | disclosed |
| EP-1115707-A1 | BENZAMIDE DERIVATIVES AND THER USE AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000018738-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064688-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | MAPK14 56/4885BRAF 1592/4885RAF1 1816/4885 |
| US-20090105230-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | MAPK14 56/4885BRAF 1592/4885RAF1 1816/4885 |
| US-20090075986-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | MAPK14 56/4885BRAF 1592/4885RAF1 1816/4885 |
| US-20090069310-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | MAPK14 56/4885BRAF 1592/4885RAF1 1816/4885 |
| US-20080045531-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | MAPK14 56/4885BRAF 1592/4885RAF1 1816/4885 |
| US-20070191336-A1 | p38 kinase inhibitors | MAPK1, MAP3K8, MAP3K1 | MAPK14 29/4885BRAF 107/4885RAF1 160/4885 |
| US-20090137021-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | MAPK14 56/4885BRAF 1592/4885RAF1 1816/4885 |
| US-20080132506-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | MAPK14 56/4885BRAF 1592/4885RAF1 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.